Annual SG&A
$795.65 M
+$24.99 M+3.24%
31 December 2023
Summary:
Alnylam Pharmaceuticals annual selling, general & administrative expenses is currently $795.65 million, with the most recent change of +$24.99 million (+3.24%) on 31 December 2023. During the last 3 years, it has risen by +$207.23 million (+35.22%). ALNY annual SG&A is now at all-time high.ALNY Selling, General & Administrative Expenses Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly SG&A
$220.99 M
-$27.40 M-11.03%
30 September 2024
Summary:
Alnylam Pharmaceuticals quarterly selling, general & administrative expenses is currently $220.99 million, with the most recent change of -$27.40 million (-11.03%) on 30 September 2024. Over the past year, it has increased by +$21.82 million (+10.95%). ALNY quarterly SG&A is now -11.03% below its all-time high of $248.40 million, reached on 30 June 2024.ALNY Quarterly SG&A Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM SG&A
-$28.38 B
-$332.26 M-1.18%
30 September 2024
Summary:
Alnylam Pharmaceuticals TTM selling, general & administrative expenses is currently -$28.38 billion, with the most recent change of -$332.26 million (-1.18%) on 30 September 2024. Over the past year, it has dropped by -$29.19 billion (-3613.14%). ALNY TTM SG&A is now -96049.86% below its all-time high of $878.31 million, reached on 30 September 2024.ALNY TTM SG&A Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
ALNY Selling, General & Administrative Expenses Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +3.2% | +10.9% | -3613.1% |
| 3 y3 years | +35.2% | +55.5% | -4825.9% |
| 5 y5 years | +108.1% | +83.6% | -6678.7% |
ALNY Selling, General & Administrative Expenses High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | at high | +35.2% | -11.0% | +55.5% | -45.4% | at low |
| 5 y | 5 years | at high | +108.1% | -11.0% | +83.6% | -126.0% | at low |
| alltime | all time | at high | >+9999.0% | -11.0% | +7398.9% | <-9999.0% | at low |
Alnylam Pharmaceuticals Selling, General & Administrative Expenses History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | $220.99 M(-11.0%) | $878.31 M(+2.5%) |
| June 2024 | - | $248.40 M(+17.8%) | $856.49 M(+4.1%) |
| Mar 2024 | - | $210.80 M(+6.4%) | $822.78 M(+3.4%) |
| Dec 2023 | $795.65 M(+3.2%) | $198.12 M(-0.5%) | $795.65 M(-1.5%) |
| Sept 2023 | - | $199.18 M(-7.2%) | $807.87 M(-4.3%) |
| June 2023 | - | $214.69 M(+16.9%) | $844.55 M(+5.6%) |
| Mar 2023 | - | $183.66 M(-12.7%) | $799.85 M(+3.8%) |
| Dec 2022 | $770.66 M(+24.2%) | $210.34 M(-10.8%) | $770.66 M(+3.2%) |
| Sept 2022 | - | $235.86 M(+38.8%) | $746.70 M(+14.4%) |
| June 2022 | - | $169.98 M(+10.0%) | $652.91 M(+3.9%) |
| Mar 2022 | - | $154.47 M(-17.1%) | $628.25 M(+1.2%) |
| Dec 2021 | $620.64 M(+5.5%) | $186.38 M(+31.2%) | $620.64 M(+3.3%) |
| Sept 2021 | - | $142.07 M(-2.2%) | $600.55 M(-4.1%) |
| June 2021 | - | $145.32 M(-1.0%) | $625.95 M(+2.9%) |
| Mar 2021 | - | $146.86 M(-11.7%) | $608.52 M(+3.4%) |
| Dec 2020 | $588.42 M(+22.8%) | $166.29 M(-0.7%) | $588.42 M(+1.7%) |
| Sept 2020 | - | $167.47 M(+30.9%) | $578.41 M(+8.9%) |
| June 2020 | - | $127.90 M(+0.9%) | $531.28 M(+2.9%) |
| Mar 2020 | - | $126.76 M(-18.9%) | $516.16 M(+7.8%) |
| Dec 2019 | $479.00 M(+25.3%) | $156.28 M(+29.9%) | $479.00 M(+11.0%) |
| Sept 2019 | - | $120.35 M(+6.7%) | $431.42 M(+0.9%) |
| June 2019 | - | $112.77 M(+25.8%) | $427.61 M(+7.0%) |
| Mar 2019 | - | $89.61 M(-17.6%) | $399.52 M(+4.5%) |
| Dec 2018 | $382.36 M(+91.8%) | $108.69 M(-6.7%) | $382.36 M(+12.1%) |
| Sept 2018 | - | $116.55 M(+37.6%) | $341.13 M(+25.3%) |
| June 2018 | - | $84.68 M(+16.9%) | $272.23 M(+16.7%) |
| Mar 2018 | - | $72.45 M(+7.4%) | $233.32 M(+17.0%) |
| Dec 2017 | $199.37 M(+123.1%) | $67.45 M(+41.6%) | $199.37 M(+24.8%) |
| Sept 2017 | - | $47.64 M(+4.1%) | $159.79 M(+18.8%) |
| June 2017 | - | $45.78 M(+18.9%) | $134.53 M(+26.0%) |
| Mar 2017 | - | $38.49 M(+38.1%) | $106.74 M(+19.5%) |
| Dec 2016 | $89.35 M(+47.4%) | $27.88 M(+24.5%) | $89.35 M(+13.5%) |
| Sept 2016 | - | $22.39 M(+24.5%) | $78.71 M(+8.8%) |
| June 2016 | - | $17.99 M(-14.8%) | $72.35 M(+4.9%) |
| Mar 2016 | - | $21.10 M(+22.5%) | $68.99 M(+13.8%) |
| Dec 2015 | $60.61 M(+36.1%) | $17.23 M(+7.4%) | $60.61 M(+5.3%) |
| Sept 2015 | - | $16.04 M(+9.7%) | $57.57 M(+11.9%) |
| June 2015 | - | $14.62 M(+14.9%) | $51.43 M(+6.4%) |
| Mar 2015 | - | $12.72 M(-10.3%) | $48.33 M(+8.5%) |
| Dec 2014 | $44.53 M | $14.19 M(+43.3%) | $44.53 M(+15.1%) |
| Sept 2014 | - | $9.90 M(-14.1%) | $38.67 M(+8.8%) |
| June 2014 | - | $11.52 M(+29.1%) | $35.54 M(+19.2%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2014 | - | $8.93 M(+7.1%) | $29.81 M(+9.8%) |
| Dec 2013 | $27.15 M(-37.9%) | $8.33 M(+23.1%) | $27.15 M(-6.3%) |
| Sept 2013 | - | $6.77 M(+17.0%) | $28.99 M(-17.3%) |
| June 2013 | - | $5.78 M(-7.7%) | $35.03 M(-13.4%) |
| Mar 2013 | - | $6.27 M(-38.4%) | $40.48 M(-7.4%) |
| Dec 2012 | $43.72 M(+14.2%) | $10.17 M(-20.6%) | $43.72 M(-1.1%) |
| Sept 2012 | - | $12.81 M(+14.1%) | $44.22 M(+9.6%) |
| June 2012 | - | $11.23 M(+18.0%) | $40.37 M(+7.5%) |
| Mar 2012 | - | $9.51 M(-10.9%) | $37.57 M(-1.9%) |
| Dec 2011 | $38.28 M(+2.4%) | $10.67 M(+19.2%) | $38.28 M(+10.0%) |
| Sept 2011 | - | $8.96 M(+6.2%) | $34.80 M(+0.1%) |
| June 2011 | - | $8.43 M(-17.6%) | $34.77 M(-4.6%) |
| Mar 2011 | - | $10.22 M(+42.2%) | $36.45 M(-2.5%) |
| Dec 2010 | $37.40 M(-6.3%) | $7.19 M(-19.4%) | $37.40 M(-13.7%) |
| Sept 2010 | - | $8.93 M(-11.7%) | $43.33 M(-3.9%) |
| June 2010 | - | $10.11 M(-9.5%) | $45.08 M(+3.9%) |
| Mar 2010 | - | $11.17 M(-14.9%) | $43.37 M(+8.7%) |
| Dec 2009 | $39.91 M(+47.2%) | $13.12 M(+22.8%) | $39.91 M(+17.2%) |
| Sept 2009 | - | $10.68 M(+27.2%) | $34.07 M(+12.6%) |
| June 2009 | - | $8.40 M(+8.8%) | $30.25 M(+4.5%) |
| Mar 2009 | - | $7.72 M(+6.1%) | $28.96 M(+6.8%) |
| Dec 2008 | $27.11 M(+15.9%) | $7.27 M(+6.0%) | $27.11 M(+6.8%) |
| Sept 2008 | - | $6.86 M(-3.4%) | $25.38 M(-4.4%) |
| June 2008 | - | $7.11 M(+21.0%) | $26.55 M(+7.4%) |
| Mar 2008 | - | $5.87 M(+6.0%) | $24.72 M(+5.7%) |
| Dec 2007 | $23.39 M(+40.6%) | $5.54 M(-31.1%) | $23.39 M(+4.1%) |
| Sept 2007 | - | $8.04 M(+52.4%) | $22.48 M(+22.0%) |
| June 2007 | - | $5.27 M(+16.1%) | $18.42 M(+4.2%) |
| Mar 2007 | - | $4.54 M(-1.9%) | $17.68 M(+5.7%) |
| Dec 2006 | $16.63 M(+19.9%) | $4.63 M(+16.2%) | $16.73 M(+5.8%) |
| Sept 2006 | - | $3.98 M(-12.1%) | $15.80 M(-0.7%) |
| June 2006 | - | $4.53 M(+26.4%) | $15.91 M(+9.7%) |
| Mar 2006 | - | $3.58 M(-3.3%) | $14.50 M(+4.6%) |
| Dec 2005 | $13.87 M(+16.2%) | $3.71 M(-9.3%) | $13.87 M(+5.4%) |
| Sept 2005 | - | $4.09 M(+30.9%) | $13.16 M(+9.4%) |
| June 2005 | - | $3.12 M(+5.8%) | $12.04 M(+1.5%) |
| Mar 2005 | - | $2.95 M(-1.6%) | $11.86 M(-0.7%) |
| Dec 2004 | $11.94 M(+58.6%) | $3.00 M(+1.2%) | $11.94 M(+33.5%) |
| Sept 2004 | - | $2.96 M(+0.5%) | $8.94 M(+49.5%) |
| June 2004 | - | $2.95 M(-2.8%) | $5.98 M(+97.2%) |
| Mar 2004 | - | $3.03 M | $3.03 M |
| Dec 2003 | $7.53 M(+755.3%) | - | - |
| Dec 2002 | $880.00 K | - | - |
FAQ
- What is Alnylam Pharmaceuticals annual selling, general & administrative expenses?
- What is the all time high annual SG&A for Alnylam Pharmaceuticals?
- What is Alnylam Pharmaceuticals annual SG&A year-on-year change?
- What is Alnylam Pharmaceuticals quarterly selling, general & administrative expenses?
- What is the all time high quarterly SG&A for Alnylam Pharmaceuticals?
- What is Alnylam Pharmaceuticals quarterly SG&A year-on-year change?
- What is Alnylam Pharmaceuticals TTM selling, general & administrative expenses?
- What is the all time high TTM SG&A for Alnylam Pharmaceuticals?
- What is Alnylam Pharmaceuticals TTM SG&A year-on-year change?
What is Alnylam Pharmaceuticals annual selling, general & administrative expenses?
The current annual SG&A of ALNY is $795.65 M
What is the all time high annual SG&A for Alnylam Pharmaceuticals?
Alnylam Pharmaceuticals all-time high annual selling, general & administrative expenses is $795.65 M
What is Alnylam Pharmaceuticals annual SG&A year-on-year change?
Over the past year, ALNY annual selling, general & administrative expenses has changed by +$24.99 M (+3.24%)
What is Alnylam Pharmaceuticals quarterly selling, general & administrative expenses?
The current quarterly SG&A of ALNY is $220.99 M
What is the all time high quarterly SG&A for Alnylam Pharmaceuticals?
Alnylam Pharmaceuticals all-time high quarterly selling, general & administrative expenses is $248.40 M
What is Alnylam Pharmaceuticals quarterly SG&A year-on-year change?
Over the past year, ALNY quarterly selling, general & administrative expenses has changed by +$21.82 M (+10.95%)
What is Alnylam Pharmaceuticals TTM selling, general & administrative expenses?
The current TTM SG&A of ALNY is -$28.38 B
What is the all time high TTM SG&A for Alnylam Pharmaceuticals?
Alnylam Pharmaceuticals all-time high TTM selling, general & administrative expenses is $878.31 M
What is Alnylam Pharmaceuticals TTM SG&A year-on-year change?
Over the past year, ALNY TTM selling, general & administrative expenses has changed by -$29.19 B (-3613.14%)